BRCA1 and breast carcinoma: In addition to BRCA1/2, the newly recommended standard therapies include an immune checkpoint inhibitor for MSI‐H, trastuzumab regimen for ERBB2 amplification, BRAF/MEK inhibitor for BRAF V600E, tyrosine kinase inhibitors for the fusion of NTRK1,3, RET, and ROS1, and everolimus for PTEN mutations or deletions in breast cancer.